In this video, Motley Fool Health-Care Analyst David Williamson breaks down just what happened in the recent Canadian Supreme Court ruling against Pfizer (PFE -0.61%). The Canadian patent on the company's drug Viagra was due to expire in 2014, but the Court struck down the patent in a unanimous ruling, invalidating the patent. Williamson explains the losers and the winners in this situation, and just how much we can expect Pfizer to really be affected.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.